| to elect seven directors to serve until the 2009 Annual Meeting or until their successors are duly elected and qualified; | |
| to ratify the appointment of Marcum & Kliegman LLP as our independent registered public accounting firm; | |
| to approve the amendment of the Restated Certificate of Incorporation; and | |
| to transact such other business as may properly come before the Annual Meeting and any adjournments or postponements of the Annual Meeting. |
Page | ||||
1 | ||||
3 | ||||
11 | ||||
20 | ||||
21 | ||||
22 | ||||
23 | ||||
24 | ||||
25 | ||||
25 |
i
| The election of directors; | |
| The approval of the amendment of the Restated Certificate of Incorporation; and | |
| The ratification of the appointment of the independent registered public accounting firm for fiscal year 2009. |
| FOR election of each of the nominated directors; | |
| FOR approval of the amendment of the Restated Certificate of Incorporation; and | |
| FOR ratification of the appointment of the independent registered public accounting firm for fiscal year 2009. |
| By Mail Sign and date each proxy card you receive and return it in the prepaid envelope. Sign your name exactly as it appears on the proxy. If you return your signed proxy but do not indicate your voting preferences, your shares will be voted on your behalf FOR the election of the nominated directors, FOR the approval of the amendment of the Restated Certificate of Incorporation, and FOR the ratification of the independent registered public accounting firm for fiscal year 2009. Stockholders of record may vote by mail or in person at the Annual Meeting. | |
| By Telephone or the Internet If you are a beneficial owner, you will receive instructions from the holder of record that you must follow in order for your shares to be voted. Telephone and Internet voting will be offered to stockholders owning shares through most banks and brokers. Follow the instructions located on your voting instruction form. Please be aware that if you vote over the Internet, you may incur costs such as telephone and Internet access charges for which you will be responsible. |
If you vote by telephone or via the Internet you do not need to return your voting instruction form to your bank or broker. |
| In Person at the Annual Meeting Shares held in your name as the stockholder of record may be voted at the Annual Meeting. Shares held beneficially in street name may be voted in person only if you obtain a legal proxy from the broker, bank or nominee that holds your shares giving you the right to vote the shares. Even if you plan to attend the Annual Meeting, we recommend that you also submit your proxy or voting instructions or vote by telephone or the Internet so that your vote will be counted if you later decide not to attend the meeting. |
2
3
Name
|
Age
|
Position with Company
|
Director Since
|
|||||||
Hojabr Alimi
|
46 | Chairman of the Board and Chief Executive Officer | 1999 | |||||||
James Schutz
|
45 | General Counsel, Vice President of Corporate Development and Secretary | 2004 | |||||||
Gregg Alton(1)(3)
|
42 | Director | 2008 | |||||||
Jay Birnbaum(1)
|
63 | Director | 2007 | |||||||
Robert Burlingame
|
74 | Director | 2006 | |||||||
Richard Conley(1)(2)(3)
|
58 | Director | 1999 | |||||||
Gregory French(2)(3)
|
47 | Director | 2000 |
(1) | Member of the Audit Committee | |
(2) | Member of the Compensation Committee | |
(3) | Member of the Nominating and Corporate Governance Committee |
4
| Robert Burlingame | |
| Jim Schutz |
| Gregg Alton | |
| Jay Birnbaum |
| Hojabr Alimi | |
| Richard Conley | |
| Gregory French |
5
Number of Members: | 3 | |
Current Members: |
Richard Conley (Chair and Audit Committee Financial Expert)
Gregg H. Alton Jay Birnbaum |
|
Number of Meetings in fiscal year 2008: | 8 | |
Functions: | The Audit Committee provides assistance to the board of directors in fulfilling its oversight responsibilities relating to the Companys financial statements, system of internal control over financial reporting, and auditing, accounting and financial reporting processes. Other specific duties and responsibilities of the Audit Committee are to appoint, compensate, evaluate and, when appropriate, replace the Companys independent registered public accounting firm; review and pre-approve audit and permissible non-audit services; review the scope of the annual audit; monitor the independent registered public accounting firms relationship with the Company; and meet with the independent registered public accounting firm and management to discuss and review the Companys financial statements, internal control over financial reporting, and auditing, accounting and financial reporting processes. |
Number of Members: | 2 | |
Current Members: |
Gregory French (Chair)
Richard Conley |
|
Number of Meetings in fiscal year 2008: | 2 | |
Functions: | The Compensation Committees primary functions are to assist the board of directors in meeting its responsibilities in regard to oversight and determination of executive compensation and to review and make recommendations with respect to major compensation plans, policies and programs of the Company. Other specific duties and responsibilities of the Compensation Committee are to review and approve goals and objectives relevant to the recommendations for approval by the independent members of the board of directors regarding compensation of our Chief Executive Officer and other executive officers, establish and approve compensation levels for our CEO and other executive officers, and to administer our stock plans and other equity-based compensation plans. |
6
Number of Members: | 3 | |
Current Members: |
Gregg Alton (Chair)
Gregory French Richard Conley |
|
Number of Meetings in fiscal year 2008: | 0 | |
Functions: | The Nominating and Corporate Governance Committees primary functions are to identify qualified individuals to become members of the board of directors, determine the composition of the board and its committees, and monitor a process to assess board effectiveness. Other specific duties and responsibilities of the Nominating and Corporate Governance Committee are to recommend nominees to fill vacancies on the board of directors, review and make recommendations to the board of directors with respect to candidates for director proposed by stockholders, and review on an annual basis the functioning and effectiveness of the board and its committees. |
7
8
Fees Earned
Option
or Paid in
Awards
All Other
Cash ($)
($)(3)(4)
Compensation ($)
Total ($)
25,000
36,081
146,000
(5)
207,081
0
5,399
0
5,399
30,000
48,169
0
78,169
30,000
36,081
0
66,081
25,000
36,081
175,000
(6)
236,081
39,000
117,608
0
156,608
32,000
59,374
0
91,374
(1)
Mr. Alton joined our board of directors on January 16,
2008.
(2)
Dr. Birnbaum joined our board of directors on
April 20, 2007.
(3)
Represents the compensation expense related to outstanding
options we recognized for the year ended March 31, 2008
under SFAS No. 123(R), Share Based
Payment, (SFAS 123(R)), rather than
amounts paid to or realized by the named individual and includes
expenses we recognized in 2008 for option grants in prior
periods. Compensation expense is determined by computing the
fair value of each option on the grant date in accordance with
SFAS 123(R) and recognizing that amount as expense ratably
over the option vesting term. See Note 13 of Notes to our
Consolidated Financial Statements set forth in our
10-K
for the
assumptions made in determining SFAS 123(R) values. The
SFAS 123(R) value of an option as of the grant date is
spread over the number of months in which the option is subject
to vesting and includes ratable amounts expensed for option
grants in prior years. There can be no assurance that options
will be exercised (in which case no value will be realized by
the individual) or that the value on exercise will approximate
the compensation expense we recognized. Related to services
rendered in 2008, Mr. Akao was granted an option to
purchase 15,000 shares of our common stock with a grant
date fair value of $74,190. Mr. Alton was granted an option
to purchase 50,000 shares of our common stock with a grant
date fair value of $198,485 upon assuming his position on the
board. Dr. Birnbaum was granted an option to purchase
50,000 shares of our common stock with a grant date fair
value of $168,915 upon assuming his position on the board.
Related to services rendered in 2008, Mr. Brown was granted
an option to purchase 15,000 shares of our common stock
with a grant date fair value of $74,190 and Mr. Burlingame
was granted an option to purchase 15,000 shares of our
common stock with a grant date fair value of $74,190.
Additionally in 2008, Mr. Conley was granted an option to
purchase 35,000 shares of our common stock with a grant
date fair value of $104,090 for services rendered in 2007, and
he was granted an additional option to purchase
15,000 shares of our common stock with a grant date fair
value of $74,190 for services rendered in 2008; and
Mr. French was granted an option to purchase
10,000 shares of our common stock with a grant date fair
value of $29,740 for services rendered in 2007, and he was
granted an additional option to purchase 15,000 shares of
our common stock with a grant date fair value of $74,190 for
services rendered in 2008.
9
Table of Contents
(4)
The following table sets forth the aggregate number of shares of
common stock underlying option awards outstanding at
March 31, 2008:
Number of
Shares
39,656
50,000
50,000
65,000
90,000
204,570
108,906
(5)
Represents amounts paid to White Moon Medical, Inc. for
consulting services rendered to the Company in fiscal 2008.
Mr. Akao is the sole stockholder of White Moon Medical, Inc.
(6)
Represents compensation expense related to outstanding warrant
to purchase 75,000 shares of our common stock we recognized
during the year ended March 31, 2008. With respect to the
warrant, on January 24, 2007, the date our registration
statement with respect to our initial public offering was
declared effective, we granted to Mr. Burlingame a warrant
to purchase 75,000 shares of our common stock with an
exercise price of $8.00, the price of common stock in our
initial public offering. This grant replaced a warrant issued to
Mr. Burlingame on November 7, 2006 to purchase
75,000 shares of common stock at $9.00, which was equal to
the midpoint of the then assumed price per share of the
Companys common stock in our initial public offering.
10
Table of Contents
Bionovo
Penwest Pharma
Cardium Therapeutics
Relidyne
Favrille
RegenRx
Inhibitex
SGX Pharma
Insmed
Somaxon
LeMaitre Vascular
Sunesis Pharma
Lev Pharma
Thermage
Novabay
Novacea
11
Table of Contents
12
Table of Contents
13
Table of Contents
14
Table of Contents
All Other
Fiscal
Stock
Option
Compensation
Year
Salary ($)
Bonus ($)
Award
Awards ($)
($)
Total ($)
2007
$
275,000
$
154,133
0
0
0
429,133
2008
275,000
279,120
0
0
8,092
(3)
562,212
2007
185,000
0
0
351,496
(1)
0
536,496
2008
185,000
92,500
0
0
4,480
281,980
2007
190,000
60,000
0
72,422
(2)
0
322,442
Development, Secretary
and General Counsel
2008
225,000
113,260
0
139,250
(2)
12,680
(4)
490,190
2007
162,308
125,000
0
137,559
(2)
0
424,867
2008
200,000
100,000
0
284,054
(2)
13,416
(5)
597,470
2007
180,000
27,500
0
27,943
(2)
12,545
(6)
247,688
Operations and Sales
2008
180,000
90,000
0
49,427
(2)
12,816
(7)
332,243
(1)
Represents the compensation expense under SFAS 123(R), that
we recognized for the year ended March 31, 2007 related to
an obligation to grant an option at the closing of our initial
public offering, which was treated as outstanding for accounting
purposes. The expense was recognized in fiscal year ended
March 31, 2007, due to the closing of our initial public
offering. Compensation expense is determined by computing the
fair value of each option on the grant date in accordance with
SFAS 123(R) and recognizing that amount as expense ratably
over the option vesting term. See Note 13 of Notes to our
Consolidated Financial Statements set forth in our
10-K
for the
assumptions made in determining SFAS 123(R) values. The
SFAS 123(R) value of an option as of the grant date is
spread over the number of months in which the option is subject
to vesting and includes ratable amounts expensed for option
grants in prior years. A restricted stock unit was granted in
lieu of the option in fiscal year 2008. The Company did not
incur incremental compensation expense related to the grant of
the restricted stock unit.
15
Table of Contents
(2)
Represents the compensation expense related to outstanding
options we recognized for the year ended March 31, 2008
under SFAS 123(R), rather than amounts paid to or realized
by the named individual, and includes expense we recognized in
2008 for option grants in prior periods. Compensation expense is
determined by computing the fair value of each option on the
grant date in accordance with SFAS 123(R) and recognizing
that amount as expense ratably over the option vesting term. See
Note 13 of Notes to our Consolidated Financial Statements
set forth in our
10-K
for the
assumptions made in determining SFAS 123(R) values. The
SFAS 123(R) value of an option as of the grant date is spread
over the number of months in which the option is subject to
vesting and includes ratable amounts expensed for option grants
in prior years. There can be no assurance that options will be
exercised (in which case no value will be realized by the
individual) or that the value on exercise will approximate the
compensation expense we recognized.
(3)
Perquisites and personal benefits include: (a) car
allowance in the amount of $6,442, and (b) matching IRA
contribution in the amount of $1,650.
(4)
Perquisites and personal benefits include: (a) car
allowance in the amount of $6,294, and (b) matching IRA
contribution in the amount of $6,387.
(5)
Perquisites and personal benefits include: (a) car
allowance in the amount of $7,200 and (b) matching IRA
contribution in the amount of $6,216.
(6)
Perquisites and personal benefits include: (a) car
allowance in the amount of $6,646 and (b) matching IRA
contribution in the amount of $5,599.
(7)
Perquisites and personal benefits include: (a) car
allowance in the amount of $7,200 and (b) matching IRA
contribution in the amount of $5,616.
Estimated
Future
Payments
All Other
All Other
Closing
Under Non-
Stock
Option
Market
Equity
Awards:
Awards:
Exercise or
Price on
Grant Date
Incentive
Number of
Number of
Base
Date of
Fair Value of
Date of
Plan
Shares of
Securities
Price of
Comp.
Stock and
Compensation
Awards(1)
Stock or
Underlying
Option
Committee
Option
Committee
Target
Units
Options
Awards
Action
Awards
Grant Date
Action
($)
(#)
(#)
($/sh)
($)
($)
N/A
N/A
279,120
(4)
N/A
N/A
N/A
N/A
0
4/26/2007
4/26/2007
92,500
60,000
(2)
N/A
3.00
6.30
(2)
0
6/15/2007
(3)
6/15/2007
113,260
(5)
N/A
100,000
7.27
7.27
482,670
6/15/2007
(3)
6/15/2007
200,000
150,001
7.27
7.27
724,010
6/15/2007
(3)
6/15/2007
90,000
N/A
25,000
7.27
7.27
120,668
(1)
Bonuses granted under the Companys 2008 Bonus Plan for
services rendered in fiscal 2008, paid subsequent to fiscal year
end in accordance with the terms of the 2008 Bonus Plan (except
where otherwise noted in the footnotes to this table).
(2)
Mr. Miller was granted 60,000 restricted stock units on
April 26, 2007, which may be settled as to one-half of the
shares on January 15, 2009 and as to the remaining one-half
of the shares on January 15, 2010. This grant was made for
services rendered by Mr. Miller in fiscal 2007 and was made
in lieu of the award of an option under the Companys 2004
Stock Option Plan authorized by the board on October 1,
2005 to be granted at the closing of our initial public
offering. The Company did not incur incremental compensation
expense related to the grant of the restricted stock unit.
(3)
Awards were authorized and approved for grant by the board of
directors on June 15, 2007. The awards were granted for
services rendered in fiscal 2007 and become exercisable pursuant
to a five year vesting schedule.
16
Table of Contents
(4)
Bonus in the amount of $275,000 awarded under 2008 Bonus Plan,
and bonus in the amount of $4,120 awarded to fund life insurance
premiums for named executive officer life insurance policy.
(5)
Bonus in the amount of $112,500 awarded under 2008 Bonus Plan,
and bonus in the amount of $760 awarded to fund life insurance
premiums for named executive officer life insurance policy.
Option Awards
Stock Awards
Equity Incentive
Market
Number of
Number of
Plan Awards:
Value of
Securities
Securities
Number of
Number of
Shares or
Underlying
Underlying
Securities
Shares or
Units of
Unexercised
Unexercised
Underlying
Option
Units of Stock
Stock That
Options
Options
Unexercised
Exercise
Option
That Have
Have Not
(#)
(#)
Unearned Options
Price
Expiration
Not Vested
Vested
Exercisable
Unexercisable
(#)
($)(1)
Date
(#)
($)
19,570
0
3.00
7/10/2013
4,000
1,000
3.00
8/07/2013
300,000
0
0.15
5/10/2014
6,041
6,459
10.16
10/01/2015
15,000
0
1.10
3/20/2010
15,000
0
0.22
10/01/2009
75,000
0
0.15
5/10/2009
34,633
0
3.00
7/10/2014
39,181
0
3.00
7/10/2014
3,020
3,230
10.16
10/01/2015
3.00
1/15/2010
60,000
123,600
40,000
10,000
3.00
9/23/2013
40,000
10,000
3.00
7/10/2014
6,250
0
3.00
7/10/2014
22,500
15,000
3.00
7/10/2014
3,020
3,230
10.16
10/01/2015
0
100,000
7.27
6/15/2017
43,751
81,248
12.00
7/27/2016
0
150,001
7.27
6/15/2017
8,000
2,000
3.00
7/10/2014
11,333
8,667
4.40
5/06/2015
34,135
36,489
10.16
10/01/2015
0
25,000
7.27
6/15/2017
(1)
Except for the option grant to Hojabr Alimi with an expiration
date of May 10, 2014 at $0.15 per share and the restricted
stock unit award to Robert Miller at $3.00 per share, the
exercise price of each option or restricted stock unit is equal
to the fair market value of our common stock on the date of
grant.
(2)
Options with an expiration date of October 1, 2015 vest
over a five-year period, becoming exercisable as to 20% of the
shares on the first anniversary of the grant date with the
remaining shares vesting monthly thereafter over the following
48 months. Options with an expiration date of May 10,
2009, July 10, 2013, and August 7, 2013 vest over a
five-year period, becoming exercisable as to 20% of the shares
on each anniversary of the grant date. Options with an
expiration date of March 20, 2010 vest over a one-year
period, becoming exercisable as to 100% of the shares on the
first anniversary of the grant date. Options with an expiration
date of October 1, 2009 and May 10, 2014 were fully
vested at grant and were immediately exercisable.
(3)
Options with an expiration date of July 10, 2014 were fully
vested at grant and were immediately exercisable. Options with
an expiration date of October 1, 2015 vest over a five-year
period, becoming exercisable as to 20% of the shares on the
first anniversary of the grant date with the remaining shares
vesting monthly thereafter over
17
Table of Contents
the following 48 months. The grant of 60,000 restricted
stock units may be settled as to one-half of the shares on
January 15, 2009 and as to the remaining one-half of the
shares on January 15, 2010.
(4)
Options with an expiration date of October 1, 2015 and
June 15, 2017 vest over a five-year period, becoming
exercisable as to 20% of the shares on the first anniversary of
the grant date with the remaining shares vesting monthly
thereafter over the following 48 months. Options with an
expiration date of September 23, 2013 and July 10,
2014 vest over a five-year period, becoming exercisable as to
20% of the shares on each anniversary of the grant date.
(5)
Options vest over a five-year period, becoming exercisable as to
20% of the shares on the first anniversary of the grant date
with the remaining shares vesting monthly thereafter over the
following 48 months.
(6)
Options with an expiration date of July 10, 2014 vest over
a five-year period, becoming exercisable as to 20% of the shares
on each anniversary of the grant date. Options with an
expiration date of May 6, 2015, October 1, 2015, and
June 15, 2017 vest over a five-year period, becoming
exercisable as to 20% of the shares on the first anniversary of
the grant date with the remaining shares vesting monthly
thereafter over the following 48 months.
18
Table of Contents
Continuation
Value of
of Health &
Unvested
Salary
Welfare
Equity
Excise Tax
Continuation
Benefits(1)
Awards(2)
& Gross-Up(3)
$
550,000
$
19,584
$
5,047
$
267,203
277,500
41,232
148,210
200,000
24,924
104,590
337,500
21,852
71,750
200,462
N/A
N/A
N/A
N/A
Continuation
of Health &
Value of
Salary
Welfare
Unvested
Excise Tax
Continuation
Benefits(1)
Equity Awards(2)
& Gross-Up(3)
see above
see above
see above
see above
see above
see above
see above
see above
see above
see above
see above
see above
see above
see above
see above
see above
180,000
0
9,734
88,226
(1)
Amount assumes the Company cost of providing health and welfare
benefits for twelve months.
(2)
The values reflect the immediate vesting of all outstanding
options and other equity awards as of termination, based on a
March 31, 2008 closing stock price of $5.06 and exclude
amounts for accelerated options that have an exercise price
higher than such closing stock price.
(3)
The assumptions used to calculate excise and associated taxes
are as follows:
19
Table of Contents
Certain Beneficial Owners and Management and Related Stockholder
Matters
Number of Shares of
Percentage of
Common Stock
Common Stock
Beneficially Owned
Beneficially Owned
1,418,111
8.7
%
1,418,111
8.7
%
137,459
*
163,227
1.0
%
89,169
*
68,030
*
234,749
1.5
%
243,886
1.5
%
129,882
*
16,667
*
0
*
2,501,180
14.5
%
*
Percentage of shares beneficially owned does not exceed one
percent.
(1)
Unless otherwise stated, the address of each beneficial owner
listed on the table is
c/o Oculus
Innovative Sciences, Inc., 1129 N. McDowell Blvd.,
Petaluma, California 94954.
(2)
Includes 436,861 shares issuable upon exercise of options
that are exercisable within 60 days of July 7, 2008.
According to a Schedule 13G filed on May 15, 2008 by
Mr. Alimi, Mr. Alimi is the beneficial owner of and
has the sole power to vote and dispose of or direct the
disposition of 435,445 shares, and Mr. Alimi is the
beneficial owner of and has shared power with Linda Alimi to
vote and dispose of or direct the disposition of
981,250 shares.
(3)
Includes 77,459 shares issuable upon exercise of options
that are exercisable within 60 days of July 7, 2008
and 50,000 shares held by The Miller 2005
Grandchildrens Trust, for which Mr. Miller is a
trustee. Mr. Miller is the beneficial owner and has shared
power with Margaret Miller, in their capacities as trustee of
The Miller 2005 Grandchildrens Trust, to vote and dispose
of or direct the disposition of 77,355 shares, and
Mr. Miller is the beneficial owner of and has the sole
power to vote and dispose of or direct the disposition of
10,000 shares.
(4)
Includes 153,227 shares issuable upon exercise of options
that are exercisable within 60 days of July 7, 2008.
(5)
Includes 89,169 shares issuable upon exercise of options
that are exercisable within 60 days of July 7, 2008.
20
Table of Contents
(6)
Includes 68,030 shares issuable upon exercise of options
that are exercisable within 60 days of July 7, 2008.
(7)
Includes 88,750 shares issuable upon exercise of options
that are exercisable within 60 days of July 7, 2008
and 75,000 shares issuable upon exercise of warrants that
are exercisable within 60 days of July 7, 2008.
(8)
Includes 201,236 shares issuable upon exercise of options
that are exercisable within 60 days of July 7, 2008.
(9)
Includes 84,218 shares issuable upon exercise of options
that are exercisable within 60 days of July 7, 2008.
(10)
Includes 16,667 shares issuable upon exercise of options
that are exercisable within 60 days of July 7, 2008.
(11)
No shares issuable upon exercise of options that are exercisable
within 60 days of July 7, 2008.
(12)
Includes 1,290,617 shares issuable upon exercise of options
and warrants that are exercisable within 60 days of
July 7, 2008.
21
Table of Contents
Robert Burlingame
Jim Schutz
Gregg Alton
Jay Birnbaum
Hojabr Alimi
Richard Conley
Gregory French
22
Table of Contents
2008
2007
288,000
289,000
248,000
478,000
536,000
767,000
23
Table of Contents
24
Table of Contents
25
Table of Contents
A-1
Table of Contents
A-2
Table of Contents
PROXY OCULUS INNOVATIVE SCIENCES, INC THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS The
undersigned hereby authorizes HOJABR ALIMI or JAMES SCHUTZ, as Proxies with full power in each to
act without the other and with the power of substitution in each, to represent and to vote all the
shares of stock the undersigned is entitled to vote at the Annual Meeting of Stockholders of Oculus
Innovative Sciences, Inc. (the Company) to be held at the
NASDAQ Marketsite, 4 Times Square, New York 10036 on August 27,
2008 at 10:00 a.m.(Eastern Time), or at any postponements or
adjournments thereof, and instructs said Proxies to vote as follows: Shares represented by this
proxy will be voted as directed by the stockholder. If no such directions are indicated, the
Proxies will have the authority to vote FOR the election of directors, FOR Proposal 2, FOR Proposal
3 and in accordance with the discretion of the Proxies on any other matters as may properly come
before the Annual Meeting of Stockholders. PLEASE MARK, DATE, SIGN, AND RETURN THIS PROXY CARD
PROMPTLY, USING THE ENCLOSED ENVELOPE. (Continued and to be voted on reverse side) Address
Change/Comments (Mark the corresponding box on the reverse side) FOLD AND DETACH HERE
Table of Contents
Mark this box with an X if you have made changes to your name or address
details above. Signature(s) x Date , 2008 NOTE:
Please sign your name(s) EXACTLY as your name(s) appear(s) on
this proxy. All joint holders must sign. When signing as attorney, trustee,
executor, administrator, guardian or corporate officer, please provide your FULL title.
FOLD AND DETACH HERE PLEASE SEE REVERSE SIDE A Election of
Directors 1. The Board of Directors recommends a vote FOR the listed nominees as
directors for the Company to serve until the next Annual Meeting of Stockholders
or until their successors are duly elected and qualified. Nominees: 01 Hojabr Alimi 05
Richard Conley 02 Gregg Alton 06 Gregory French 03 Jay Birnbaum 07 James Schutz 04
Robert Burlingame WITHHOLD AUTHORITY to vote for the following Directors: FOR WITHHOLD
2. To ratify the appointment of Marcum & Kliegman LLP as the Companys Independent
Registered Public Accounting Firm 3. To approve the amendment of the Companys
Restated Certificate of Incorporation. FOR AGAINST ABSTAIN
C. Authorized Signatures -Sign Here -This section must be completed for your
instructions to be executed. 4. In their discretion, the Proxies are authorized
to vote upon such other business as may properly come before the meeting or any
postponement or adjournment thereof. This proxy when properly executed will
be voted in the manner directed herein by the undersigned stockholder. If no
direction is given, this proxy will be voted FOR the election of directors
listed above, FOR Proposal 2 and FOR Proposal 3. B Proposals The Board of
Directors recommends a vote FOR the following proposals: